Advancing evidence-generating medicine

Osmind’s research is helping to set new standards for mental health interventions and improve patient outcomes. See how we work with research partners to generate real-world evidence to accelerate advances in mental health care.

Doctor treating patient at his office

Selected research projects

Mar 15, 2024

A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic

Hagai et al. (2024). Oxford Ketamine Conference.

Mar 7, 2024

Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians

Feb 13, 2024

Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines

McInnes and Marton (2024). Current Psychiatry Research and Reviews.

Feb 11, 2024

Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence

McInnes, Marton, Qian (2024). Journal of Affective Disorders.

Dec 8, 2023

Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)

Kane, Worley, McInnes (2023). American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Meeting.

Dec 6, 2023

Using a longitudinal model to predict outcomes to ketamine intravenous therapy for depression

Kane, Worley, McInnes (2023). American College of Neuropharmacology Annual Meeting.

Lets transform mental health together

Click here to learn more about our research or to discuss collaboration opportunities.

Company team chatting at an informal reunion
Learn more about Osmind’s research and real-world evidence
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.